Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Phytochem Rev
2009 Jun 01;82:415-429. doi: 10.1007/s11101-009-9120-1.
Show Gene links
Show Anatomy links
Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.
Nagle DG
,
Zhou YD
.
???displayArticle.abstract???
Marine natural products have become a major source of new chemical entities in the discovery of potential anticancer agents that potently suppress various antitumor molecular targets. As a consequence of insufficient vascularization, hypoxic regions form within rapidly growing solid tumor masses. Specific alterations of gene expression in these hypoxic tumor cells help facilitate the survival and metastatic spread of solid tumors. The transcriptional response to cellular hypoxia is primarily mediated by the transcription factor hypoxia-inducible factor-1 (HIF-1) that regulates the expression of more than 100 genes involved in cellular adaptation and survival under hypoxic stress. Clinical studies in cancer patients indicate that HIF-1 activation is directly correlated with advanced disease stages and treatment resistance. HIF-1 has emerged as an important tumor-selective molecular target for anticancer drug discovery. As a result, natural product-based inhibitors of HIF-1 activation have been identified from plants and microorganisms. Recently, structurally unique natural products from marine sponges, crinoids, and algae have been identified as HIF-1 activation inhibitors. The US National Cancer Institute's Open Repository of marine invertebrate and algae extracts has proven to be a valuable source of natural product HIF-1 inhibitors. Among the active compounds identified, certain marine natural products have also been shown to suppress the hypoxic induction of HIF-1 target genes such as vascular endothelial growth factor (VEGF). Some of these marine HIF-1 inhibitors act by interfering with the generation of mitochondrial signaling molecules in hypoxic cells. However, the precise mechanisms of action for many newly identified marine natural product HIF-1 inhibitors remain unresolved.
Ahuja,
Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation.
2000, Pubmed
Ahuja,
Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation.
2000,
Pubmed
Axelson,
Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors.
2005,
Pubmed
Baby,
Role of mitochondria in the regulation of hypoxia-inducible factor-1alpha in the rat carotid body glomus cells.
2005,
Pubmed
Bell,
The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production.
2007,
Pubmed
Bell,
Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria.
2008,
Pubmed
Birner,
Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.
2000,
Pubmed
Bos,
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
2001,
Pubmed
Broggini,
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
2003,
Pubmed
Brown,
Exploiting tumour hypoxia in cancer treatment.
2004,
Pubmed
Caers,
Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.
2008,
Pubmed
Cairns,
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.
2007,
Pubmed
Chandel,
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription.
1998,
Pubmed
Chau,
Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.
2005,
Pubmed
Chittiboyina,
Total synthesis and absolute configuration of laurenditerpenol: a hypoxia inducible factor-1 activation inhibitor.
2007,
Pubmed
Covens,
A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
2006,
Pubmed
Crews,
GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha.
1994,
Pubmed
Dai,
Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells.
2006,
Pubmed
Dai,
Benzochromenones from the marine crinoid Comantheria rotula inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines.
2007,
Pubmed
,
Echinobase
Dai,
Cytotoxic metabolites from an Indonesian sponge Lendenfeldia sp.
2007,
Pubmed
Dai,
Hypoxia-selective antitumor agents: norsesterterpene peroxides from the marine sponge Diacarnus levii preferentially suppress the growth of tumor cells under hypoxic conditions.
2007,
Pubmed
El Sayed,
Bioactive natural and semisynthetic latrunculins.
2006,
Pubmed
Erba,
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.
2002,
Pubmed
Fang,
Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression.
2008,
Pubmed
Gachet,
A MAP kinase-dependent actin checkpoint ensures proper spindle orientation in fission yeast.
2001,
Pubmed
Gong,
Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells.
2005,
Pubmed
González-Santiago,
Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation.
2006,
Pubmed
Graeber,
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.
1996,
Pubmed
Greenberger,
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
2008,
Pubmed
Greijer,
Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1).
2005,
Pubmed
Guzy,
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing.
2005,
Pubmed
Hodges,
Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1.
2004,
Pubmed
Hossain,
Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1.
2005,
Pubmed
Isaacs,
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway.
2002,
Pubmed
Ivan,
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
2001,
Pubmed
Jaakkola,
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
2001,
Pubmed
Jones,
Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding.
2006,
Pubmed
Klimova,
Mitochondrial complex III regulates hypoxic activation of HIF.
2008,
Pubmed
Kong,
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
2005,
Pubmed
Kung,
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.
2004,
Pubmed
Lando,
Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.
2002,
Pubmed
Li,
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
2006,
Pubmed
Lin,
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation.
2008,
Pubmed
Liu,
RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.
2007,
Pubmed
Liu,
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
2007,
Pubmed
Liu,
Molecular-targeted antitumor agents. 19. Furospongolide from a marine Lendenfeldia sp. sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells.
2008,
Pubmed
Maluf,
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.
2006,
Pubmed
Marcu,
Tirapazamine: from bench to clinical trials.
2006,
Pubmed
Maxwell,
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
1999,
Pubmed
Melillo,
Targeting hypoxia cell signaling for cancer therapy.
2007,
Pubmed
Mitsiades,
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
2008,
Pubmed
Mizokami,
Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas.
2006,
Pubmed
Moeller,
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.
2005,
Pubmed
Mohammed,
Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells.
2004,
Pubmed
Mohammed,
Strongylophorines: natural product inhibitors of hypoxia-inducible factor-1 transcriptional pathway.
2008,
Pubmed
Muñoz-Alonso,
Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells.
2008,
Pubmed
Nagle,
Mechanism targeted discovery of antitumor marine natural products.
2004,
Pubmed
Nagle,
Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).
2006,
Pubmed
Nagle,
Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).
2006,
Pubmed
Nakaseko,
Cell biology. Cytoskeleton in the cell cycle.
2001,
Pubmed
Newman,
Marine natural products and related compounds in clinical and advanced preclinical trials.
2004,
Pubmed
Newman,
Natural products as sources of new drugs over the last 25 years.
2007,
Pubmed
Pan,
Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.
2007,
Pubmed
Park,
Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha.
2003,
Pubmed
Rapisarda,
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
2002,
Pubmed
Rapisarda,
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
2004,
Pubmed
Raval,
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
2005,
Pubmed
Rischin,
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
2005,
Pubmed
Ryan,
Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.
2000,
Pubmed
Sayed,
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.
2008,
Pubmed
Semenza,
Targeting HIF-1 for cancer therapy.
2003,
Pubmed
Semenza,
Development of novel therapeutic strategies that target HIF-1.
2006,
Pubmed
Semenza,
Evaluation of HIF-1 inhibitors as anticancer agents.
2007,
Pubmed
Semenza,
Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1.
2007,
Pubmed
Semenza,
A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.
1992,
Pubmed
Simon,
Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization.
2006,
Pubmed
Sipos,
The therapeutic management of differentiated thyroid cancer.
2008,
Pubmed
Sowter,
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia.
2003,
Pubmed
Spector,
Latrunculins: novel marine toxins that disrupt microfilament organization in cultured cells.
1983,
Pubmed
Spector,
Latrunculins--novel marine macrolides that disrupt microfilament organization and affect cell growth: I. Comparison with cytochalasin D.
1989,
Pubmed
Straight,
Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
2006,
Pubmed
Tan,
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
2005,
Pubmed
Tatum,
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.
2006,
Pubmed
Unruh,
The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.
2003,
Pubmed
Urdiales,
Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates.
1996,
Pubmed
Vaux,
Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain.
2001,
Pubmed
Wang,
Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.
1993,
Pubmed
Warabi,
Strongylophorine-26, a new meroditerpenoid isolated from the marine sponge Petrosia (Strongylophora) corticata that exhibits anti-invasion activity.
2004,
Pubmed
Zhong,
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
1999,
Pubmed
Zhou,
Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells.
2005,
Pubmed
von Pawel,
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.
2000,
Pubmed
